The Use of Fluorescein Angiography in Acquired Macular Diseases

The Use of Fluorescein Angiography in Acquired Macular Diseases

Antonio P. Ciardella

Stephen R. Kaufman

Lawrence A. Yannuzzi

Fluorescein angiography (FA) has been widely used clinically for more than 3 decades, and it has been valuable in the understanding, diagnosis, and treatment of acquired macular diseases. Extensive use of FA, combined with growing knowledge of the range of clinical presentations and natural histories of the acquired macular diseases, has helped clinicians obtain an appreciation of the indications for FA. Our aim in this chapter is to illustrate useful parameters of FA and to provide guidance for the optimal use of this technique. Comprehensive reviews of the interpretation of the fluorescein angiogram may be found elsewhere.1,2



FA is needed to assess response to laser photocoagulation of a CNV and to diagnose recurrent membranes.51,54 The authors generally obtain angiograms 2 weeks, 1 month, 3 months, and 6 months after treatment. The risk of recurrence is greatest during the first 3 months, and the patient, who often has decreased vision due to prior neurosensory detachment, may be asymptomatic. FA is also needed to evaluate the results of PDT. In the original protocol of the Verteporfin in Photodynamic Therapy (VIP) and Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) studies, a fluorescein angiogram was obtained every 3 months, and if there was persistent leakage from the CNV PDT was applied again (see Fig. 1820).60


Jul 11, 2016 | Posted by in OPHTHALMOLOGY | Comments Off on The Use of Fluorescein Angiography in Acquired Macular Diseases
Premium Wordpress Themes by UFO Themes